Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. [electronic resource]
Producer: 20150127Description: 1207-14 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Ovarian Epithelial
- Cisplatin -- administration & dosage
- Confidence Intervals
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Phthalazines -- administration & dosage
- Piperazines -- administration & dosage
- Quinazolines -- administration & dosage
- Risk Assessment
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.